ArticleOrganic letters2008
The first synthesis of a novel 5:7:5-fused diimidazodiazepine ring system and some of its chemical properties.
Article in Organic letters, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Design, synthesis, and anticancer assessment of structural analogues of (RSC medicinal chemistry · 2024Article
- DDX3X structural analysis: Implications in the pharmacology and innate immunity.Current research in immunology · 2022Review
- Design and Synthesis of Non-Covalent Imidazo[1,2-Molecules (Basel, Switzerland) · 2021Article
- Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanismRSC medicinal chemistry · 2020Article
- Article
- A Simple Precursor for Highly Functionalized Fused Imidazo[4,5-b]pyridines and Imidazo[4,5-b]-1,8-naphthyridine.Molecules (Basel, Switzerland) · 2016Article
- In vitro anti-cancer activity of doxorubicin against human RNA helicase, DDX3.Bioinformation · 2016Article
- DDX3, a potential target for cancer treatment.Molecular cancer · 2015Review
- NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.Oncotarget · 2015Article
- PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.Cancer chemotherapy and pharmacology · 2015Article
- Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.Scientific reports · 2015Article
- Structure-based drug design and potent anti-cancer activity of tricyclic 5:7:5-fused diimidazo[4,5-d:4',5'-f][1,3]diazepines.Bioorganic & medicinal chemistry · 2013Article
- Article
- Novel, Broad Spectrum Anti-Cancer Agents Containing the Tricyclic 5:7:5-Fused Diimidazodiazepine Ring System.ACS medicinal chemistry letters · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The first synthesis of a novel 5:7:5-fused heterocyclic ring system, a diimidazodiazepine, is reported. The propensity of the ring system to undergo facile, acid-catalyzed nucleophilic addition reactions by neutral carbon and nitrogen nucleophiles has been explored. The ring system has potential future applications in mechanistic studies of formation and repair of DNA interstrand cross-links.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.